Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. reported that Chief Legal Officer John G. Saia received a grant of 20,448 restricted stock units tied to Guardant Health common stock. These RSUs were awarded on March 11, 2026 as part of his equity compensation and do not involve any cash share purchases or sales.
According to the vesting schedule, 33% of the RSUs will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Saia directly holds 20,448 RSUs, which will convert into common shares only as they vest.
Monroe Terilyn J. reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief People Officer Terilyn J. Monroe received a grant of 17,040 Restricted Stock Units on March 11, 2026. These RSUs represent the right to receive an equal number of Guardant common shares as they vest over time.
According to the award terms, 33% of the RSUs will vest on April 1, 2027, and the remaining 67% will vest in equal quarterly installments over the following two years. After this grant, Monroe holds 17,040 RSUs directly, reflecting a routine equity compensation award rather than an open‑market purchase or sale.
Kalia Kumud reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Information Officer Kalia Kumud received a grant of 13,632 restricted stock units (RSUs) on March 11, 2026. The award vests over three years: 33% on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Kumud holds 13,632 RSUs directly.
Freeman Chris reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. reported that Chief Commercial Officer Chris Freeman received a grant of 18,744 restricted stock units. These RSUs, which represent rights to receive an equal number of common shares, were awarded as compensation and involve no cash purchase or market trade.
The award granted on March 11, 2026 vests over three years: 33% of the units vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, Freeman holds 18,744 RSUs directly.
Guardant Health, Inc. Chief Technology Officer Darya Chudova reported a grant of 23,856 restricted stock units. The award was granted on March 11, 2026 and will convert into an equal number of common shares as it vests. According to the vesting schedule, 33% of the units will vest on April 1, 2027, with the remaining 67% vesting in equal quarterly installments over the following two years. After this grant, her reported direct holdings in this award total 23,856 restricted stock units.
Bell Michael Brian reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell received a grant of 26,582 restricted stock units on March 11, 2026 as equity compensation. The award vests over three years: 33% on April 1, 2027 and the remaining 67% in equal quarterly installments over the following two years, settling in common stock as units vest.
Guardant Health, Inc. director Manuel Hidalgo Medina reported option exercises and share sales in company stock. On March 6, 2026, he exercised a stock option for 1,000 shares at a price of $0.00 per share, receiving 1,000 shares of common stock valued at $32.55 per share in the transaction record.
The same day, he sold a total of 1,300 shares of common stock in open-market transactions at average prices of $91.6065 and $91.3001 per share, leaving him with 1,193 common shares held directly after the sales. The underlying stock option was originally granted on July 17, 2024 and vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years.
Guardant Health insiders reported proposed sales and recent transactions under Form 144. The filing lists restricted stock lapses of 101 shares on 08/17/2025 and 199 shares on 09/17/2025, and a stock option exercise resulting in 1,000 shares on 03/06/2026 (broker payment for cashless exercise). The excerpt also shows a reported sale of 1,250 shares by Manuel Hidalgo Medina on 12/08/2025 for $131,250.
Guardant Health Chief Information Officer Kumud Kalia exercised stock options and sold shares on March 4, 2026. He exercised multiple stock option awards, converting them into common stock at exercise prices including $47.20, $74.00, $32.86, $28.37, and $28.61 per share.
On the same date, he sold a total of 40,000 shares of Guardant Health common stock in open-market transactions at weighted average prices of about $95.12 and $95.73 per share, across ranges disclosed in the footnotes. After these trades, he directly held 37,643 shares of common stock.
The option awards he exercised were originally granted between April 20, 2020 and November 8, 2024 and vest over three- or four-year schedules, with initial portions vesting on specified dates and remaining shares vesting in equal monthly installments thereafter.
Guardant Health, Inc. submitted a Rule 144 notice for the proposed sale of 40,000 common shares on 03/04/2026. The filing lists Charles Schwab & Co., Inc. as the broker and identifies the method as a Broker Payment for Cashless Exercise.
An earlier sale by Kumud Kalia of 2,000 shares on 12/08/2025 for $209,204.00 is reported as securities sold during the past three months.